Promising Alternative Therapeutics for Oral Candidiasis

Rodrigues, Célia Fortuna; Rodrigues, Maria Elisa; Henriques, Mariana

doi:10.2174/0929867325666180601102333

Cited by 33 publications

(21 citation statements)

References 119 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Probiotic bacteria are capable of stimulating specific and nonspecific defense mechanisms in a human body. The use of probiotics is recommended when the immunity of an organism weakens, which lowers the risk of the occurrence of inflammation, allergies, or infection [ 78 , 79 ].…”

Section: Effectiveness In Promoting Health: Mechanism Of Action Ofmentioning

confidence: 99%

Probiotics: Versatile Bioactive Components in Promoting Human Health

et al. 2020

Self Cite

View full text Add to dashboard Cite

The positive impact of probiotic strains on human health has become more evident than ever before. Often delivered through food, dietary products, supplements, and drugs, different legislations for safety and efficacy issues have been prepared. Furthermore, regulatory agencies have addressed various approaches toward these products, whether they authorize claims mentioning a disease’s diagnosis, prevention, or treatment. Due to the diversity of bacteria and yeast strains, strict approaches have been designed to assess for side effects and post-market surveillance. One of the most essential delivery systems of probiotics is within food, due to the great beneficial health effects of this system compared to pharmaceutical products and also due to the increasing importance of food and nutrition. Modern lifestyle or various diseases lead to an imbalance of the intestinal flora. Nonetheless, as the amount of probiotic use needs accurate calculations, different factors should also be taken into consideration. One of the novelties of this review is the presentation of the beneficial effects of the administration of probiotics as a potential adjuvant therapy in COVID-19. Thus, this paper provides an integrative overview of different aspects of probiotics, from human health care applications to safety, quality, and control.

show abstract

Section: Effectiveness In Promoting Health: Mechanism Of Action Ofmentioning

confidence: 99%

Probiotics: Versatile Bioactive Components in Promoting Human Health

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…With poor response to standard antimicrobials and the deficiency in developing new antifungal agents into the clinic, it stands that alternate means of treating the fungal diseases are warranted. In this context, the use of probiotics has been considered a promising strategy for prevention and control of several fungal infections (Mailander-Sanchez et al, 2012 ; Matsubara et al, 2016a ; Hu et al, 2017 ; Rodrigues C. F. et al, 2019 ). Probiotics are live microorganisms or microbial cell components that beneficially affect host health (Guarner et al, 2012 ; Janczarek et al, 2016 ; Matsubara et al, 2016b ; Rossoni et al, 2018 ), but their clinical application in immunocompromised patients is limited due to the possibility of bacteremia caused by bacteria of the genus Lactobacillus (Cannon et al, 2005 ; Salminen et al, 2006 ).…”

Section: Introductionmentioning

confidence: 99%

The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris

Rossoni

Barros

Mendonça

et al. 2020

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Candida auris has emerged as a medically important pathogen with considerable resistance to antifungal agents. The ability to produce biofilms is an important pathogenicity feature of this species that aids escape of host immune responses and antimicrobial agents. The objective of this study was to verify antifungal action using in vitro and in vivo models of the Lactobacillus paracasei 28.4 probiotic cells and postbiotic activity of crude extract (LPCE) and fraction 1 (LPF1), derived from L. paracasei 28.4 supernatant. Both live cells and cells free supernatant of L. paracasei 28.4 inhibited C. auris suggesting probiotic and postbiotic effects. The minimum inhibitory concentration (MIC) for LPCE was 15 mg/mL and ranges from 3.75 to 7.5 mg/mL for LPF1. Killing kinetics determined that after 24 h treatment with LPCE or LPF1 there was a complete reduction of viable C. auris cells compared to fluconazole, which decreased the initial inoculum by 1-logCFU during the same time period. LPCE and LPF1 significantly reduced the biomass ( p = 0.0001) and the metabolic activity ( p = 0.0001) of C. auris biofilm. There was also a total reduction (~10 8 CFU/mL) in viability of persister C. auris cells after treatment with postbiotic elements ( p < 0.0001). In an in vivo study, injection of LPCE and LPF1 into G. mellonella larvae infected with C. auris prolonged survival of these insects compared to a control group ( p < 0.05) and elicited immune responses by increasing the number of circulating hemocytes and gene expression of antimicrobial peptide galiomicin. We concluded that the L. paracasei 28.4 cells and postbiotic elements (LPCE and LPF1) have antifungal activity against planktonic cells, biofilms, and persister cells of C. auris . Postbiotic supplementation derived from L. paracasei 28.4 protected G. mellonella infected with C. auris and enhanced its immune status indicating a dual function in modulating a host immune response.

show abstract

“…This increase in C. glabrata infections is related to an inherent low susceptibility to azoles [10,11], and can also be a result of rare mutations that are selected by drug pressure [12]. Accordingly, the cases of fluconazole-refractory disease (resistance to fluconazole) associated with C. glabrata are common in candidiasis.…”

Section: Introductionmentioning

confidence: 99%

Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms

2018

View full text Add to dashboard Cite

Candidemia cases have been increasing, especially among immunosuppressed patients. Candida glabrata is one of the most resistant Candida species, especially to the azole drugs, resulting in a high demand for therapeutic alternatives. The minimum inhibitory concentration (MIC), minimum fungicidal concentration (MFC), and minimum biofilm eradication concentration (MBEC) were determined for posaconazole (Pcz) and amphotericin B (AmB). The drug combinations of both drugs were evaluated on pre-formed biofilms of C. glabrata ATCC 2001, through XTT (2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay, colony forming units (CFU), crystal violet, and the fractional inhibitory concentration index (FICI). C. glabrata revealed higher susceptibility and biofilm reduction in the presence of AmB alone, but both drugs revealed a good capacity in the biomass elimination. In the majority of the tested combinations, the interactions were defined as indifferent (FICI ≤ 4). The combination of the two drugs does not seem to bring a clear advantage in the treatment of biofilms of C. glabrata.

show abstract

Promising Alternative Therapeutics for Oral Candidiasis

Abstract: The findings of this review confirm the importance and the urgency of the development of efficacious therapies for oral candidal infections.

Cited by 33 publications

References 119 publications

Probiotics: Versatile Bioactive Components in Promoting Human Health

Probiotics: Versatile Bioactive Components in Promoting Human Health

The Postbiotic Activity of Lactobacillus paracasei 28.4 Against Candida auris

Combination of Posaconazole and Amphotericin B in the Treatment of Candida glabrata Biofilms

Contact Info

Product

Resources

About